YESAccepted98% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
Yes. The exact trial named in the question, NCT05668013 (RELIEVE UCCD long-term extension), has a sponsor-announced public readout on February 17, 2026. Both Sanofi and Teva explicitly describe this exact Phase 2b maintenance/LTE study as having positive results with clinically meaningful, durable efficacy in ulcerative colitis and Crohn’s disease.
Found Mar 30, 2026, 4:36 AMOutcome date Feb 17, 2026, 12:00 AMReviewed Mar 30, 2026, 7:04 AM
Sponsorsanofi.comFeb 17, 2026, 12:00 AM
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Sanofi states that positive results from the RELIEVE UCCD long-term extension study, identified as NCT05668013, showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease who initially responded to induction. The release headline also says the phase 2b maintenance data demonstrated clinically meaningful durable efficacy.
Sponsortevapharm.comFeb 17, 2026, 12:00 AM
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Teva states that positive results from the RELIEVE UCCD long-term extension study showed durable clinical and endoscopic efficacy maintained over 44 weeks in ulcerative colitis and Crohn’s disease. The release identifies RELIEVE UCCD LTE as the double-blind randomized study evaluating long-term efficacy, safety, and tolerability of duvakitug in UC and CD.